Business Context and Reporting Period
This Form 8-K Current Report was filed by Aquestive Therapeutics, Inc. on August 16, 2018, covering events occurring on August 15, 2018. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing details a specific capital raising event rather than periodic financial performance metrics.
- Transaction Type: Sale of common stock pursuant to the partial exercise of an over-allotment option.
- Shares Sold: 425,727 shares.
- Price Per Share: $15.00 (before underwriting discount).
- Underwriters: Syndicate led by BMO Capital Markets Corp. and RBC Capital Markets, LLC.
- Revenue, Profit, Cash Flow, Debt, and Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change reported is the increase in outstanding common stock and the associated cash inflow from the sale of 425,727 shares. No other material changes to operations or financial position are detailed in this specific report.
Guidance, Outlook, and Risks
The filing does not contain updated guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard disclosure of the equity transaction. The event is categorized under Item 8.01 (Other Events).
Investor Verification Checklist
- Verify the total gross proceeds from the sale of 425,727 shares at $15.00 per share.
- Confirm the specific underwriting discount amount to calculate net proceeds.
- Review the full text of the press release (Exhibit 99.1) for details on the use of proceeds.
- Check the updated total number of outstanding shares following this issuance.